Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma

BACKGROUND: Cabozantinib was established as the standard of care for the treatment of patients with renal cell carcinoma (RCC) whose disease had progressed after vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) therapy in the global randomized trial METEOR. A phase 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakaigawa, Noboru, Tomita, Yoshihiko, Tamada, Satoshi, Tatsugami, Katsunori, Osawa, Takahiro, Oya, Mototsugu, Kanayama, Hiroomi, Miura, Yuji, Sassa, Naoto, Nishimura, Kazuo, Nozawa, Masahiro, Masumori, Naoya, Miyoshi, Yasuhide, Kuroda, Shingo, Kimura, Akiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988754/
https://www.ncbi.nlm.nih.gov/pubmed/36595123
http://dx.doi.org/10.1007/s10147-022-02283-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988754/
https://www.ncbi.nlm.nih.gov/pubmed/36595123
http://dx.doi.org/10.1007/s10147-022-02283-w

Ejemplares similares